HIND
Vyome Holdings Inc
NASDAQ · Pharmaceuticals
$2.74
+0.44 (+19.13%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.00M | 5.84M | 4.87M |
| Net Income | 1.15M | 1.21M | 947.3K |
| EPS | — | — | — |
| Profit Margin | 19.1% | 20.8% | 19.4% |
| Rev Growth | +1.1% | -9.0% | -7.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 7.33M | 7.09M | 8.20M |
| Total Equity | 8.72M | 9.03M | 10.37M |
| D/E Ratio | 0.84 | 0.79 | 0.79 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.77M | 1.81M | 1.57M |
| Free Cash Flow | 589.5K | 575.3K | 579.0K |